Back to results
US 9,040,493 B2Granted
RNA antagonists targeting GLI2 for the treatment of leukemia
AssigneeSantaris Pharma A/S
InventorsYixian Zhang, Zhengxing Qu
Life of this patent
Estimating the term…
Abstract
The present invention relates to oligomer compounds (oligomers) for the treatment and prevention of acute myeloid leukemia, which target GLI2 mRNA in a cell, leading to reduced expression of GLI2.
Claims13
A method for treating acute myeloid leukaemia or pre-leukaemia, comprising administering to a patient an oligomer consisting of 10-30 nucleobases wherein the oligomer is perfectly complementary to a corresponding region of SEQ ID NO:1, all linkages between nucleobases are phosphorothioate linkages, and comprises nucleotide analogues having a modified sugar.
Dependencies are inferred from the claim text.